Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

[1]  Hongchao Li,et al.  Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer , 2019, Clinical Drug Investigation.

[2]  P. Postmus,et al.  Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  David M. Phillippo,et al.  Population Adjustment Methods for Indirect Comparisons: A Review of National Institute for Health and Care Excellence Technology Appraisals , 2019, International Journal of Technology Assessment in Health Care.

[4]  Yi-Ju Lin,et al.  Patient preferences for diabetes-related complications in Taiwan , 2019, Current medical research and opinion.

[5]  Junlong Li,et al.  Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls , 2018, Current medical research and opinion.

[6]  Anand A. Dalal,et al.  Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States , 2018, Journal of medical economics.

[7]  S. Ou,et al.  410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study , 2017 .

[8]  Jeffrey W. Scott,et al.  ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Sofia Dias,et al.  Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  A. DunnGalvin,et al.  Quality of life in childhood, adolescence and adult food allergy: Patient and parent perspectives , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[12]  J. Carlson,et al.  The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib , 2017, Journal of medical economics.

[13]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[14]  Jipan Xie,et al.  Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada , 2016, Journal of medical economics.

[15]  R. Beckerman,et al.  Cost-Effectiveness of Ceritinib Versus Current Therapies for Chemotherapy-Experienced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients in Mexico. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  C. Zhang,et al.  Cost-Effectiveness Of Ceritinib In The Treatment Of Previously Treated Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In The United Kingdom. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  A. Adler,et al.  NICE guidance on nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[18]  G. Scagliotti,et al.  ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). , 2015 .

[19]  F. Cappuzzo,et al.  Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). , 2015 .

[20]  Sydney Rosen,et al.  Thresholds for the cost–effectiveness of interventions: alternative approaches , 2014, Bulletin of the World Health Organization.

[21]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[22]  J. Vansteenkiste,et al.  Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  Y. Bang,et al.  Treatment of ALK-positive non-small cell lung cancer. , 2012, Archives of pathology & laboratory medicine.

[25]  P. Iyengar,et al.  Isolated central nervous system progression on Crizotinib , 2012, Cancer biology & therapy.

[26]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[27]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[28]  Peter Clark,et al.  The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study , 2010, PloS one.

[29]  B. Cowling,et al.  Cost effectiveness of mammography screening for Chinese women , 2007, Cancer.

[30]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[31]  G. Imbens,et al.  Estimation of Causal Effects using Propensity Score Weighting: An Application to Data on Right Heart Catheterization , 2001, Health Services and Outcomes Research Methodology.

[32]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[33]  Renato Martins,et al.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[35]  H. Kong.  The Government of the Hong Kong Special Administrative Region , 2002 .